Enovis (ENOV) Scheduled to Post Earnings on Thursday

Enovis (NYSE:ENOV) is set to release its earnings data before the market opens on Thursday, May 2nd. Analysts expect Enovis to post earnings of $0.50 per share for the quarter. Enovis has set its FY 2024 guidance at 2.500-2.650 EPS and its FY24 guidance at $2.50-$2.65 EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.76 by $0.03. Enovis had a positive return on equity of 3.84% and a negative net margin of 1.95%. The firm had revenue of $455.00 million for the quarter, compared to analysts’ expectations of $444.34 million. During the same quarter last year, the business earned $0.72 EPS. The company’s quarterly revenue was up 11.2% compared to the same quarter last year. On average, analysts expect Enovis to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Enovis Trading Up 1.1 %

ENOV opened at $55.89 on Tuesday. The company has a quick ratio of 1.16, a current ratio of 2.43 and a debt-to-equity ratio of 0.14. Enovis has a twelve month low of $43.04 and a twelve month high of $66.14. The company has a 50-day simple moving average of $59.80 and a 200 day simple moving average of $55.65.

Analyst Ratings Changes

ENOV has been the subject of a number of recent analyst reports. UBS Group initiated coverage on shares of Enovis in a report on Monday, January 22nd. They set a “buy” rating and a $75.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $82.00 target price on shares of Enovis in a report on Wednesday, April 10th. Stephens initiated coverage on Enovis in a research report on Tuesday, February 13th. They set an “overweight” rating and a $72.00 price objective for the company. William Blair initiated coverage on shares of Enovis in a research report on Wednesday, January 3rd. They set an “outperform” rating for the company. Finally, Canaccord Genuity Group boosted their target price on shares of Enovis from $73.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $75.43.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.